According to filings with the U.S. Securities and Exchange Commission, Somite Therapeutics, Inc. is raising up to $47,499,943.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Somite Therapeutics, Inc.
Somite.ai is developing AI foundation models for human stem cells to drive novel cell therapies at scale. We take a full-stack approachgenerating data at 1,000x lower cost, training large-scale models with unmatched predictive power, and using these models to discover, refine, and optimize high-impact applications in cell therapy. Our founding team includes repeat AI entrepreneur Dr. Micha Breakstone (Chorus.ai, acquired for $575M), the Head of the Fundamental AI Group at MIT (pioneered the foundational research on scaling laws), and four Harvard Medical School professors and National Academy of Sciences/Medicine members, including the Chair of the Genetics Department at HMS. Based in Boston and launching operations in January 2024, Somite has raised over $11M in pre-seed funding.

To learn more about Somite Therapeutics, Inc., visit https://www.somite.ai/
Somite Therapeutics, Inc. Linkedin Page: https://www.linkedin.com/company/somite-therapeutics/

Contact:
Micah Breakstone, Chief Executive Officer
512-270-9113

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.